

Shmuel Vasser
DECHERT LLP
1095 Avenue of the Americas
New York, New York 10036
Telephone: (212) 698-3500
Facsimile: (212) 698-3599
Email: shmuel.vasser@dechert.com

*Special Counsel for Debtors
and Debtors in Possession*

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

**PURDUE PHARMA L.P., et al.,

Debtors.¹**

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**NOTICE OF AMENDED SUMMARY STATEMENT FOR SECOND INTERIM FEE
APPLICATION OF DECHERT LLP, SPECIAL COUNSEL FOR THE DEBTORS,
FOR COMPENSATION FOR PROFESSIONAL SERVICES RENDERED AND
REIMBURSEMENT OF ACTUAL AND NECESSARY EXPENSES INCURRED**

PLEASE TAKE NOTICE that on July 15, 2020, Dechert LLP filed the *Second Interim Fee Application of Dechert LLP, Special Counsel for the Debtors, for Compensation for Professional Services Rendered and Reimbursement of Actual and Necessary Expenses Incurred* [ECF No. 1399] (the “**Second Interim Fee Application**”).

¹ The Debtors in these cases, along with the last four digits of each Debtor’s registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors’ corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

PLEASE TAKE FURTHER NOTICE that included in the Second Interim Fee Application is a Summary Statement (the “**Summary Statement**”).

PLEASE TAKE FURTHER NOTICE that Dechert LLP corrected the Summary Statement (the “**Amended Summary Statement**”). A copy of the Amended Summary Statement is attached hereto as **Exhibit A**.

PLEASE TAKE FURTHER NOTICE that a comparison between the Summary Statement and the Amended Summary Statement is attached hereto as **Exhibit B**.

PLEASE TAKE FURTHER NOTICE that copies of the Second Interim Fee Application and the Amended Summary Statement may be obtained free of charge by visiting the website of Prime Clerk LLC at <https://restructuring.primeclerk.com/purduepharma>. You may also obtain copies of any pleadings by visiting the Bankruptcy Court’s website at <http://www.nysb.uscourts.gov> in accordance with the procedures and fees set forth therein.

Dated: July 17, 2020
New York, New York

/s/ Shmuel Vasser
Shmuel Vasser
DECHERT LLP
1095 Avenue of the Americas
New York, New York 10036
Telephone: (212) 698-3500
Facsimile: (212) 698-3599
Email: shmuel.vasser@dechert.com

Special Counsel for Debtors and Debtors in Possession

EXHIBIT A

Amended Summary Statement

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

**PURDUE PHARMA L.P., et al.,

Debtors.²**

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**AMENDED SUMMARY STATEMENT FOR SECOND INTERIM FEE
APPLICATION OF DECHERT LLP, SPECIAL COUNSEL FOR THE DEBTORS,
FOR COMPENSATION FOR PROFESSIONAL SERVICES RENDERED AND
REIMBURSEMENT OF ACTUAL AND NECESSARY EXPENSES INCURRED**

Name of applicant	Dechert LLP
Name of client	Purdue Debtors and Debtors in Possession
Time period covered by this application	February 1, 2020 through and including May 31, 2020
Total compensation sought this period	\$3,434,410.64 ³
Total expenses sought this period	\$408,656.15 ⁴
Petition date	September 15, 2019
Retention date	<i>nunc pro tunc</i> to November 21, 2019

² The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

³ This amount reflects a reduction in fees in the amount of \$749,304.36 on account of the following voluntary discounts: (i) a voluntary discount of \$740,042.25 for aggregate fees as described in the *Application of Debtors for Authority to Retain and Employ Dechert LLP as Special Counsel to the Debtors Nunc Pro Tunc to the Petition Date* [Docket No. 424] (the "**Retention Application**") and *Dechert LLP's First Notice of Increase in Hourly Rates for Patent Services* [Docket No. 965] (the "**Notice of Increased Patent Fees**"); and (ii) a voluntary discount of \$8,085 for transient and suspect timekeepers due to concerns previously raised by the Fee Examiner. Additionally, this amount is \$1,177.11 less than the aggregate amount of the Monthly Fee Statements due to minor mistakes in use of billing rates as reflected in fn. 2 to Exhibit C.

⁴ This amount reflects an adjustment in meal expenses, lowering the amount sought for individual meals to \$20.

Date of order approving employment	November 21, 2019
Total compensation approved by interim order to date	\$5,238,965.98
Total expenses approved by interim order to date	\$815,614.96
Total allowed compensation paid to date	\$5,238,965.98
Total allowed expenses paid to date	\$815,614.96
Blended rate in this application for all attorneys	\$872.96
Blended rate in this application for all timekeepers	\$769.26
Compensation sought in this application already paid (or credited against prepetition retainer) pursuant to a monthly compensation order but not yet allowed	\$2,754,938.18 ⁵
Expenses sought in this application already paid (or credited against prepetition retainer) pursuant to a monthly compensation order but not yet allowed	\$408,656.15 ⁶
Number of professionals included in this application	67
If applicable, number of professionals in this application not included in staffing plan approved by client	N/A
If applicable, difference between fees budgeted and compensation sought for this period	Amount Budgeted: \$5,455,000 – 5,860,000 ⁷ Amount Sought: \$3,434,410.64
Number of professionals billing fewer than 15 hours to the case during this period	28
Are any rates higher than those approved or disclosed at retention? If yes, calculate and disclose the total compensation sought in this application using the rates originally disclosed in the retention application	Yes. Dechert increased its hourly rates for the Patent Services effective as of February 1, 2020 [Docket No. 965]. Using the original rates for the Patent Services the total compensation for the Fee Period would have been: \$3,428,763.68

This is a(n): ____Monthly __X__Interim ____Final application.

This application includes 459.7 hours with a value of \$138,007.23 incurred in connection with the preparation of Fee Applications for the Debtors.⁸

⁵ This amount assumes no objections are raised to Dechert's Fifth Monthly Fee Statement for the Period from May 1, 2020 Through May 31, 2020 [ECF No. 1331].

⁶ This amount assumes no objections are raised to Dechert's Fifth Monthly Fee Statement for the Period from May 1, 2020 Through May 31, 2020 [ECF No. 1331].

⁷ The budget includes amounts budgeted in the Bankruptcy Related Budget, which was mistakenly prepared to cover fees through April 30, 2020, rather than through May 31, 2020; however, this mistake is of no consequence, because Dechert's fees within these categories are either well below or within the estimated fees.

⁸ A breakdown of the fees attributed to time spent on retention and fee applications since the Petition date reflecting the aggregate discount can be found at **Exhibit H**.

SUMMARY OF MONTHLY FEE STATEMENTS

<i>Application</i>	<i>Total Compensation and Expenses Incurred for Period Covered</i>			<i>Total Amount Requested in Fee Statements</i>		<i>Total Unpaid</i>
Date Filed/Docket No.	Period Covered	Total Fees	Expenses	Fees (80%)	Expenses (100%)	Fees and Expenses
04/20/2020 Docket No. 1065	02/01/2020- 02/29/2020	\$825,205.95	\$108,937.50	\$660,164.76	\$108,937.50	\$165,041.19
04/28/2020 Docket No. 1095	03/01/2020- 03/31/2020	\$705,835.49	\$114,355.29	\$564,668.39	\$114,355.29	\$141,167.10
05/30/2020 Docket No. 1195	04/01/2020- 04/30/2020	\$1,020,788.86	\$181,824.00	\$816,631.09	\$181,824.00	\$204,157.77
07/02/2020 Docket No. 1331	05/01/2020- 05/31/2020	\$891,842.45	\$3,539.36	\$713,473.96	\$3,539.36	\$178,368.49
Totals:		\$3,443,672.75	\$408,656.15	\$2,754,938.18	\$408,656.15	\$688,734.55

EXHIBIT B

Redline

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

**PURDUE PHARMA L.P., et al.,

Debtors.¹**

Chapter 11

**Case No. 19-23649 (RDD)

(Jointly Administered)**

**AMENDED SUMMARY STATEMENT FOR SECOND INTERIM FEE APPLICATION
APPLICATION OF DECHERT LLP, SPECIAL COUNSEL FOR THE DEBTORS,
FOR COMPENSATION FOR PROFESSIONAL SERVICES RENDERED AND
REIMBURSEMENT OF ACTUAL AND NECESSARY EXPENSES INCURRED**

Name of applicant	Dechert LLP
Name of client	Purdue Debtors and Debtors in Possession
Time period covered by this application	February 1, 2020 through and including May 31, 2020
Total compensation sought this period	\$3,434,410.64 ²
Total expenses sought this period	\$408,656.15 ³
Petition date	September 15, 2019
Retention date	<i>nunc pro tunc</i> to November 21, 2019

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

² This amount reflects a reduction in fees in the amount of \$749,304.36 on account of the following voluntary discounts: (i) a voluntary discount of \$740,042.25 for aggregate fees as described in the *Application of Debtors for Authority to Retain and Employ Dechert LLP as Special Counsel to the Debtors Nunc Pro Tunc to the Petition Date* [Docket No. 424] (the "**Retention Application**") and *Dechert LLP's First Notice of Increase in Hourly Rates for Patent Services* [Docket No. 965] (the "**Notice of Increased Patent Fees**"); and (ii) a voluntary discount of \$8,085 for transient and suspect timekeepers due to concerns previously raised by the Fee Examiner. Additionally, this amount is \$1,177.11 less than the aggregate amount of the Monthly Fee Statements due to minor mistakes in use of billing rates as reflected in fn. 2 to Exhibit C.

³ This amount reflects an adjustment in meal expenses, lowering the amount sought for individual meals to \$20.

Date of order approving employment	November 21, 2019
Total compensation approved by interim order to date	\$5,238,965.98
Total expenses approved by interim order to date	\$815,614.96
Total allowed compensation paid to date	\$5,238,965.98
Total allowed expenses paid to date	\$815,614.96
Blended rate in this application for all attorneys	\$872.96
Blended rate in this application for all timekeepers	\$769.26
Compensation sought in this application already paid (or credited against prepetition retainer) pursuant to a monthly compensation order but not yet allowed	\$2,754,938.18 ⁴
Expenses sought in this application already paid (or credited against prepetition retainer) pursuant to a monthly compensation order but not yet allowed	\$408,656.15 ⁵
Number of professionals included in this application	67
If applicable, number of professionals in this application not included in staffing plan approved by client	N/A
If applicable, difference between fees budgeted and compensation sought for this period	Amount Budgeted: \$5,455,000 – 5,860,000 ⁶ Amount Sought: \$3,434,410.64
Number of professionals billing fewer than 15 hours to the case during this period	28
Are any rates higher than those approved or disclosed at retention? If yes, calculate and disclose the total compensation sought in this application using the rates originally disclosed in the retention application	No. Yes. Dechert increased its hourly rates for the Patent Services effective as of February 1, 2020 [Docket No. 965]. Using the original rates for the Patent Services the total compensation for the Fee Period would have been: \$3,428,763.68

This is a(n): ☐ Monthly ☒ Interim ☐ Final application.

This application includes 459.7 hours with a value of \$138,007.23 incurred in connection with the preparation of Fee Applications for the Debtors.⁷

⁴ This amount assumes no objections are raised to Dechert's Fifth Monthly Fee Statement for the Period from May 1, 2020 Through May 31, 2020 [ECF No. 1331].

⁵ This amount assumes no objections are raised to Dechert's Fifth Monthly Fee Statement for the Period from May 1, 2020 Through May 31, 2020 [ECF No. 1331].

⁶ The budget includes amounts budgeted in the Bankruptcy Related Budget, which was mistakenly prepared to cover fees through April 30, 2020, rather than through May 31, 2020; however, this mistake is of no consequence, because Dechert's fees within these categories are either well below or within the estimated fees.

⁷ A breakdown of the fees attributed to time spent on retention and fee applications since the Petition date reflecting the aggregate discount can be found at **Exhibit H**.

SUMMARY OF MONTHLY FEE STATEMENTS

<i>Application</i>	<i>Total Compensation and Expenses Incurred for Period Covered</i>			<i>Total Amount Requested in Fee Statements</i>		<i>Total Unpaid</i>
Date Filed/Docket No.	Period Covered	Total Fees	Expenses	Fees (80%)	Expenses (100%)	Fees and Expenses
04/20/2020 Docket No. 1065	02/01/2020- 02/29/2020	\$825,205.95	\$108,937.50	\$660,164.76	\$108,937.50	\$165,041.19
04/28/2020 Docket No. 1095	03/01/2020- 03/31/2020	\$705,835.49	\$114,355.29	\$564,668.39	\$114,355.29	\$141,167.10
05/30/2020 Docket No. 1195	04/01/2020- 04/30/2020	\$1,020,788.86	\$181,824.00	\$816,631.09	\$181,824.00	\$204,157.77
07/02/2020 Docket No. 1331	05/01/2020- 05/31/2020	\$891,842.45	\$3,539.36	\$713,473.96	\$3,539.36	\$178,368.49
Totals:		\$3,443,672.75	\$408,656.15	\$2,754,938.18	\$408,656.15	\$688,734.55

Summary report: Litera® Change-Pro for Word 10.2.0.10 Document comparison done on 7/17/2020 4:41:38 PM	
Style name: Dechert Default	
Intelligent Table Comparison: Active	
Original filename: Purdue - Cover Page for Second Interim Fee Application.docx	
Modified filename: Purdue - Amended Summary Statement for Second Interim Fee Application.docx	
Changes:	
Add	3
Delete	2
Move From	0
Move To	0
Table Insert	0
Table Delete	0
Table moves to	0
Table moves from	0
Embedded Graphics (Visio, ChemDraw, Images etc.)	0
Embedded Excel	0
Format changes	0
Total Changes:	5